On this page
KCNQ2 epileptic encephalopathy
This condition is caused by changes in the KCNQ2 gene, which plays a critical role in brain function. It typically presents in the first few days or weeks of life with difficult-to-control seizures and can lead to developmental challenges.
Available at Jeen Health
Clinical tests that include this
Overview
KCNQ2 epileptic encephalopathy is a rare neurological disorder that primarily affects infants and children. It is characterised by the onset of seizures, usually within the first few days or weeks of life, often accompanied by global developmental delay [PMID:33671207]. The severity of symptoms can vary significantly among individuals, ranging from milder forms with relatively good developmental outcomes to severe forms involving profound developmental impairment and intractable seizures. This condition is caused by genetic changes in the KCNQ2 gene, which is essential for normal brain electrical activity.
The condition is considered an epileptic encephalopathy because the frequent seizures and abnormal brain activity are thought to contribute to, or worsen, developmental and cognitive difficulties. Early diagnosis and intervention are important for managing the seizures and supporting developmental progress.
Symptoms & clinical features
The primary symptoms of KCNQ2 epileptic encephalopathy are seizures, which typically begin very early in life, often within the first week [PMID:24077366]. These seizures can be varied in type, including tonic-clonic seizures (involving stiffening and jerking of muscles), focal seizures (affecting one part of the brain), or myoclonic seizures (brief, shock-like jerks). In some infants, seizures may be resistant to standard anti-epileptic medications.
Beyond seizures, developmental delay is a common feature. This can affect various areas, including motor skills (e.g., sitting, crawling, walking), speech and language development, and cognitive abilities. The degree of developmental delay is variable; some individuals experience mild delays, while others have significant intellectual disability. Some children may also experience feeding difficulties and problems with muscle tone, such as hypotonia (low muscle tone).
Video: Genetics 101
Affected organs
KCNQ2 epileptic encephalopathy primarily affects the brain and central nervous system. The KCNQ2 gene plays a crucial role in the electrical excitability of brain cells (neurons). When this gene is not functioning correctly, it disrupts the normal electrical signals in the brain, leading to seizures and impacting overall brain development and function. As a result, the primary organs affected are those involved in neurological processes, including cognitive function, motor control, and sensory processing.
Risks & severity
The severity of KCNQ2 epileptic encephalopathy can vary widely. Some individuals experience severe, intractable seizures and profound developmental delay, while others may have milder seizures that are more easily controlled and achieve better developmental milestones [PMID:33671207]. The onset of seizures is typically in the neonatal period (first 28 days of life).
Long-term outcomes depend on seizure control and the extent of developmental impairment. While some children may eventually achieve seizure freedom and make significant developmental progress, others may continue to experience seizures and require lifelong support for developmental challenges. The exact prevalence of KCNQ2 epileptic encephalopathy is not well established, but it is considered a rare condition.
Genetic causes
KCNQ2 epileptic encephalopathy is caused by pathogenic variants, also known as mutations, in the KCNQ2 gene. This gene provides instructions for making a protein that forms a part of a potassium channel. These channels are crucial for controlling the flow of potassium ions across cell membranes, which helps regulate the electrical activity of excitable cells, particularly neurons in the brain.
When a pathogenic variant occurs in KCNQ2, the potassium channel may not function correctly. This can lead to an imbalance in the electrical signals within the brain, increasing neuronal excitability and making individuals more prone to seizures. The type of genetic change can influence the severity of the condition, with some changes leading to a more severe disruption of channel function and thus more significant symptoms.
- KCNQ2 potassium voltage-gated channel subfamily Q member 2
Inheritance pattern
KCNQ2 epileptic encephalopathy is inherited in an autosomal dominant pattern. This means that a person only needs to inherit one copy of the altered KCNQ2 gene from one parent to develop the condition. In many cases, the genetic change occurs spontaneously (de novo) in the affected individual and is not inherited from either parent. In such instances, neither parent carries the pathogenic variant.
If a parent has KCNQ2 epileptic encephalopathy, each of their children has a 50% chance of inheriting the altered gene and developing the condition. Genetic counselling is recommended for affected individuals and their families to understand the inheritance pattern and recurrence risks.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of KCNQ2 epileptic encephalopathy is typically suspected based on clinical features, especially early-onset seizures and developmental delay. An electroencephalogram (EEG) may be performed to record brain electrical activity and identify seizure patterns or other abnormalities. Neuroimaging, such as an MRI of the brain, may also be conducted to look for any structural brain abnormalities, although often none are found.
The definitive diagnosis is made through genetic testing, which identifies pathogenic variants in the KCNQ2 gene. This can be done via gene panel testing, which looks at multiple genes associated with epilepsy, or whole exome sequencing. In the UK, genetic testing for early-onset epileptic encephalopathy is available through the NHS Genomic Medicine Service (GMS), often initiated by paediatricians or neurologists, and may correspond to an R-number such as R29 (Developmental and epileptic encephalopathy).
Management & lifestyle
Management of KCNQ2 epileptic encephalopathy focuses on controlling seizures and supporting developmental progress. Seizure management typically involves anti-epileptic medications, which are chosen based on the type and frequency of seizures. Finding the most effective medication or combination of medications can sometimes be challenging and may require input from a specialist paediatric neurologist. Some individuals may respond to specific medications that target potassium channels.
Developmental support is also crucial and may include a range of therapies such as physiotherapy, occupational therapy, and speech and language therapy. These therapies aim to help individuals achieve their developmental potential and improve their quality of life. Regular follow-up with a multidisciplinary team, including neurologists, therapists, and genetic counsellors, is important to monitor progress and adapt treatment plans as needed.
UK care pathway
In the UK, individuals suspected of having KCNQ2 epileptic encephalopathy would typically be managed within the NHS. This usually involves referral to a paediatric neurologist or a clinical genetics service. Genetic testing, often under the NHS Genomic Medicine Service (GMS) pathways (e.g., using relevant R-codes from the National Genomic Test Directory like R29 for Developmental and epileptic encephalopathy), would be arranged to confirm a diagnosis. Genetic counsellors play a vital role in explaining test results, inheritance patterns, and implications for the wider family.
Frequently asked questions
What is the typical outlook for someone with KCNQ2 epileptic encephalopathy?
The outlook varies significantly between individuals. Some may have severe, difficult-to-control seizures and significant developmental challenges, while others experience milder symptoms and better developmental progress. Early and ongoing therapeutic interventions can help improve outcomes.
Can KCNQ2 epileptic encephalopathy be cured?
Currently, there is no cure for KCNQ2 epileptic encephalopathy. Treatment focuses on managing symptoms, primarily controlling seizures with medication, and providing supportive therapies to aid development. Research into genetic therapies is ongoing for many genetic conditions.
If my child has KCNQ2 epileptic encephalopathy, what does this mean for future children?
If the genetic change in your child occurred spontaneously (de novo), the chance of it happening again in a future child is very low, but not zero. If one parent carries the genetic change, the risk for future children would be 50% for each pregnancy. Genetic counselling can provide personalised risk assessments.
Are there different types of KCNQ2-related conditions?
Yes, while KCNQ2 epileptic encephalopathy is often severe, pathogenic variants in KCNQ2 can also cause a milder condition called self-limiting familial neonatal epilepsy (SLFNE), where seizures typically resolve within a few months and development is usually normal. The specific genetic change often determines which condition develops.
How is KCNQ2 epileptic encephalopathy diagnosed in the UK?
Diagnosis in the UK is typically made by a paediatric neurologist or clinical geneticist. After clinical assessment and potentially an EEG, genetic testing (often a gene panel or whole exome sequencing) is performed through the NHS Genomic Medicine Service to identify a pathogenic variant in the KCNQ2 gene.
References
- Chen J, Tao Q, Fan L. Pyridoxine-responsive KCNQ2 epileptic encephalopathy: Additional cases and literature review. Molecular genetics & genomic medicine. 2022. PMID: 35906921
- Zeng Z, Xu Y, Chen C. Automatic and Quantitative Electroencephalographic Characterization of Drug-Resistant Epilepsy in Neonatal KCNQ2 Epileptic Encephalopathy. IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society. 2023. PMID: 37440383
- Legros L, Adle-Biassette H, Dozières-Puyravel B. Neuropathology findings in KCNQ2 neonatal epileptic encephalopathy. Seizure. 2022. PMID: 35584591
- Kasinathan A, Sankhyan N, Singhi P. KCNQ2 Epileptic Encephalopathy in Early Infancy. Indian journal of pediatrics. 2017. PMID: 28631195
- Zhang J, Kim EC, Chen C. Identifying mutation hotspots reveals pathogenetic mechanisms of KCNQ2 epileptic encephalopathy. Scientific reports. 2020. PMID: 32179837
- Weckhuysen S, Ivanovic V, Hendrickx R. Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients. Neurology. 2013. PMID: 24107868
- Lee IC, Chang MY, Liang JS. Ictal and interictal electroencephalographic findings can contribute to early diagnosis and prompt treatment in KCNQ2-associated epileptic encephalopathy. Journal of the Formosan Medical Association = Taiwan yi zhi. 2021. PMID: 32863083
- Kim EC, Zhang J, Pang W. Reduced axonal surface expression and phosphoinositide sensitivity in K(v)7 channels disrupts their function to inhibit neuronal excitability in Kcnq2 epileptic encephalopathy. Neurobiology of disease. 2018. PMID: 30008368